Table 5.

Patients on Study ≥ 4 Months

Tumor	SAHA dose (mg)	No. of Prior Systemic Therapy	Best Response	On-Study Duration (months)
Solid tumor
Thyroid	200 qd	1	SD	22
Renal cell*	400 qd	3	SD	4
Urothelial	200 bid	3	SD	10
Thyroid	200 bid	1	SD	28
Thyroid	300 bid	1	SD	28+
Mesothelioma	300 bid × 3 days/week	1	SD	8+
Mesothelioma	300 bid × 3 days/week	5	PR††	8
Mesothelioma†	300 bid × 3 days/week	2	SD	5
Mesothelioma	300 bid × 3 days/week	0	SD	5
Mesothelioma	300 bid × 3 days/week	1	PR††	6
Mesothelioma‡	400 bid × 3 days/week	1	SD	10
Thyroid	400 bid × 3 days/week	1	SD	12
Laryngeal§	400 bid	1	PR	10
Renal cell¶	400 bid	4	SD	37+
Thyroid∥	400 bid	1	PR	34
Thyroid**	400 bid	2	SD	37+
Hematologic malignancy
Hodgkin’s lymphoma	400 qd	2	SD	10
Hodgkin’s lymphoma	400 qd	8	SD	5
DLBCL (de novo)	600 qd	4	PR	5
DLBCL (transformed)	200 bid	3	SD	8
Cutaneous T-cell	200 bid	5	SD	4
DLBCL (transformed)	400 bid	8	CR	13

Abbreviations: SAHA, suberoylanilide hydroxamic acid; qd, every day; SD, stable disease; bid, twice a day; PR, partial response; DLBCL, diffuse large B-cell lymphoma; CR, complete response.

^*400 qd for 7 weeks; 200 qd for 9 weeks.

^†300 bid × 3 days/week for 4 weeks; 200 bid × 3 days/week for 14 weeks.

^‡400 bid × 3 days/week for 33 weeks; 300 bid for 7 weeks.

^§400 bid for 2 weeks; 400 qd for 36 weeks.

^¶400 bid for 12 weeks; 400 qd for 136+ weeks.

^∥400 bid for 4 weeks; 400 qd for 132 weeks.

^**400 bid for 93 weeks; 400 qd for 53+ weeks

^††Unconfirmed.